Milestones and Key Events
Un-blinded rapid virologic response (RVR) and early virologic response (EVR) data from the on-going Phase 2b study of RG7227 plus SOC (un-boosted 12-week regimens)
Late Q1 or early Q2 2010 (updated guidance with additional data reported)
Initiation of INFORM-2 program (ritonavir-boosted RG7227 plus RG7128)
Q1 2010: Timing subject to change due to integration of new ritonavir boosting strategy
Initiation of longer duration DAA study to evaluate SVR (ritonavir boosted)
Q2 2010: Timing subject to change due to integration of new ritonavir boosting strategy
Initiation of Phase 2b study of ritonavir-boosted RG7227 plus SOC
Q3 2010 (new study)
Subscribe to our Free Newsletters!
Ballistic exercise is characterized by rapid and jerky bouncing movements. These movements stretch ...
Chickenpox is a contagious viral infection commonly seen in the younger age group. This quiz looks ...
Summer is a time for fun but the hot weather brings with it a host of diseases. With some health ...View All